Secukinumab

Indications & Dose:

Psoriatic arthritis | Ankylosing spondylitis

• BY SUBCUTANEOUS INJECTION

Adult: 150 mg every week for 5 doses, then maintenance 150 mg every month, review treatment if no response within 16 weeks of initial dose

Psoriatic arthritis with concomitant moderate to severe plaque psoriasis or if inadequate response to anti-TNFa treatment | Plaque psoriasis

• BY SUBCUTANEOUS INJECTION

Adult: 300 mg every week for 5 doses, then maintenance 300 mg every month, review treatment if no response within 16 weeks of initial dose

Contraindications:

Severe active infection 

Side Effects:

Common or very common Diarrhoea . oral herpes . rhinorrhoea . upper respiratory tract infections

Uncommon Conjunctivitis . neutropenia (usually mild and reversible) .
oral candidiasis . otitis externa . tinea pedis

Rare Anaphylactic reactions
PREGNANCY Manufacturer advises avoid—no information available.
BREAST FEEDING Manufacturer advises avoid during treatment and for up to 20 weeks after discontinuing treatment—no information available

Cautions:

Chronic infection . Crohn’s disease (monitor for exacerbations) . history of recurrent infection . predisposition to infection (discontinue if new serious infection develops) 

Precautions:

Interaction:

Warnings:

Adverse Effects:

Lactations:

Special Precautions:

Counselling:

Side Effects Or Adverse Reactions:

Patient And Carer Advice: